 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that it will participate in the Jefferies Cell &amp; Genetic Medicine Summit, to be held from September...

Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit

Latest Ratings for SGMO
 DateFirmActionFromTo May 2021RBC CapitalInitiates Coverage OnOutperform Jan 2021StifelInitiates Coverage OnHold Dec 2020HC Wainwright & Co.AssumesBuy
 View More Analyst Ratings for SGMO

 View the Latest Analyst Ratings

read more...

Analyst Ratings for Sangamo Therapeutics

Sangamo Therapeutics GAAP EPS of -$0.66 misses by $0.32, revenue of $6.84M misses by $8.49M

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results. I am extremely proud of our significant progress this quarter. We are pleased to have executed several business development deals...

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Sangamo Therapeutics Q2 2023 Earnings Preview

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a clinical-stage genomic medicine company and Chroma Medicine, Inc. (Chroma), a genomic medicine company pioneering single-dose epigenetic editing...

Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing

Sangamo Therapeutics, Inc. (Sangamo, Nasdaq: SGMO), a genomic medicine company, today announced it has signed an evaluation and option agreement with Prevail Therapeutics (Prevail), a wholly owned subsidiary of Eli Lilly and Company, through which Prevail has been granted rights to evaluate certain...

Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids

Investors eyeing a purchase of Sangamo Therapeutics Inc (SGMO) shares, but cautious about paying the going market price of 1.32/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2024 ...

Commit To Buy Sangamo Therapeutics At $1, Earn 18.6% Annualized Using Options

Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence...

Following a 68% decline over last year, recent gains may please Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for...

Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Watchers	10,861
52-Wk Low	$0.5982
52-Wk High	$5.17

Market Cap	$106.14M
Volume (M)	1.13M
52-Wk High	$5.17
52-Wk Low	$0.5982

SGMO Sangamo Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals